Tracks kidney function in prostate cancer patients receiving lutetium radioligand therapy
Follows kidney function over time in men with advanced prostate cancer receiving lutetium therapy.
Plain-language title generated from the registry record
Registry title: Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial
Key facts
- Where
- Munich, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with metastatic castration-resistant prostate cancer who are starting 177Lu-PSMA radioligand therapy at the Klinikum rechts der Isar. Their kidney function is followed over time.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Metastatic castration-resistant prostate cancer (mCRPC)
- Earlier treatment
- Must be starting their first cycle of 177Lu-PSMA radioligand therapy at the Klinikum rechts der Isar.
Main reasons for not taking part
- Missing or incomplete informed consent
- Age below 18 years
Read by machine on 12 November 2026.
Where in Germany
- Klinikum rechts der Isar, München, Bavaria 81675Munich, GermanyContact: Hannah/Christoph Schäfer/SchmadererTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hannah Schaefer
- Trial code
- NCT06720532
- Record updated
- 6 December 2024
- Original description
The goal of this observational study is to determine the impact of 177Lutetium-Prostate Specific Membrane Antigen (PSMA) Radioligand Therapy (177Lu-PSMA-RLT) on kidney function over time. The main question it aims to answer is:Read full original descriptionShow less
177Lu-PSMA-KiRi-trial
The goal of this observational study is to determine the impact of 177Lutetium-Prostate Specific Membrane Antigen (PSMA) Radioligand Therapy (177Lu-PSMA-RLT) on kidney function over time. The main question it aims to answer is:
What is the absolute decline in estimated glomerular filtration rate (eGFR) in patients undergoing 177Lu-PSMA-RLT after 12 and 24 months?
Patients treated with 177Lu-PSMA-RLT will have their kidney function monitored before, during, and after therapy using routine markers like creatinine and cystatin C. Additional biomarkers and urine proteomics will be collected to identify early detection markers and risk factors for chronic kidney disease (CKD). Follow-up examinations will be conducted at regular intervals up to 5 years. The study also aims to correlate clinical risk factors and patient-reported outcomes with kidney insufficiency to assess the impact of therapy and identify vulnerable patient groups.
Inclusion: Patients with mCRPC starting 177Lu-PSMA RLT at the Klinikum rechts der Isar at the time of therapy initiation (1st cycle).
Exclusion: age below 18 years; Missing or incomplete informed consent.